Term ends no later than Dec 2, 2027 · Low confidence
20-year base term ends Dec 28, 2026
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Pharmacyclics LLC
Filed Jan 20, 2009 as application 12/356,498 · Granted Jan 3, 2012
Base term plus 339 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Dec 28, 2006
Dec 28, 2006
Ends no later than
Dec 2, 2027
Dec 2, 2027
Granted
Jan 3, 2012
Jan 3, 2012
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
339
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
76
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 339 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 28, 2006, when application 11/617,645, the earliest non-provisional in its chain, was filed (this one was filed Jan 20, 2009); a parent in its chain could not be resolved (the next row) | Dec 28, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +339 days, USPTO patent term adjustment record | Dec 2, 2027 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Dec 2, 2027 | Low confidence |
This family
| US 7,514,444 | In force no later than Dec 2026 | no later than Dec 2026 |
| US 7,732,454 | In force Apr 2027 | Apr 2027 |
| US 7,825,118 | In force Jan 2028 | Jan 2028 |
| Application PCT/US2008/058528 | PCT application no patent term | no patent term |
| US 8,088,781 | this patent no later than Dec 2027 | no later than Dec 2027 |
| Application 12/499,008 | Abandoned not computed | not computed |
| US 8,008,309 | In force Nov 2027 | Nov 2027 |
| US 8,501,751 | In force Dec 2026 | Dec 2026 |
8 of 76 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 10, 2009 Reel 22230, frame 205 | Honigberg, Lee; Verner, Erik; Pan, Zhengying | Pharmacyclics, Inc. | Assignment of Assignor's Interest |
| Nov 14, 2011 Reel 27224, frame 964 | Mody, Tarak D. | Pharmacyclics, Inc. | Assignment of Assignor's Interest |
| Jul 16, 2015 Reel 36126, frame 377 | Oxford Amherst Corporation | Pharmacyclics, Inc. | Merger |
| Jul 16, 2015 Reel 36126, frame 398 | Pharmacyclics, Inc.; Oxford Amherst LLC | Pharmacyclics LLC | Merger and Change of Name |
| May 17, 2016 Reel 38722, frame 776 | Oxford Amherst Corporation; Pharmacyclics, Inc. | Pharmacyclics, Inc. | Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036126 Frame 0377. Assignor(S) Hereby Confirms the Merger. |
| May 17, 2016 Reel 38722, frame 849 | Pharmacyclics, Inc.; Oxford Amherst LLC | Pharmacyclics LLC | Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036126 Frame 0398. Assignor(S) Hereby Confirms the Merger and Change of Name. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2027
Term ends no later than Dec 2, 2027. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 339 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Dec 2, 2027. We will not guess the cap.
Citations
248
later US patents cite this one
That is top 5% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.